

Supplementary Table S1

Supplementary Table S1. Baseline demographics and disease characteristics of the ADACTA safety and bio-repository populations

	Safety population N = 324		Bio-repository population N = 184	
	ADA 40 mg SC q2w n=162	TCZ 8 mg/kg IV q4w n=162	ADA 40 mg SC q2w n=97	TCZ 8 mg/kg IV q4w n=87
Female, n (%)	133 (82)	129 (80)	75 (77)	69 (79)
Age, years	53.3 (12.43)	54.3 (12.94)	54.3 (12.61)	53.4 (12.94)
Weight, kg	78.5 (19.64)	76.0 (17.39)	79.2 (18.64)	77.8 (18.04)
Ethnicity, n (%)				
Hispanic	31 (19)	20 (12)	19 (20)	9 (10)
Non-Hispanic	131 (81)	142 (88)	78 (80)	78 (90)
Geographic region				
North America	59 (36)	62 (38)	33 (34)	39 (45)
Non-North America	103 (64)	100 (62)	64 (66)	48 (55)
Duration of RA, years	6.3 (6.94)	7.3 (8.06)	6.7 (7.09)	6.8 (7.80)
RF positive, n (%)	119 (73)	121 (75)	68 (70)	59 (68)
Anti-CCP positive, n (%)	117 (72)	126 (78)	67 (69)	61 (70)
Number of previous DMARDs	2.0 (1.06)	2.0 (1.06)	2.0 (1.11)	2.0 (1.13)
Oral corticosteroid use, n (%)	92 (57)	89 (55)	49 (51)	42 (48)
Previous and concomitant use of lipid-lowering agents, n (%) ^a	35 (22)	38 (23)	17 (18%)	11(13%)
TJC (68 joints)	30.5 (16.71)	29.3 (15.01)	29.5 (17.12)	27.7 (14.38)
SJC (66 joints)	17.6 (10.80)	16.1 (10.52)	16.8 (10.14)	16.2 (11.01)
DAS28	6.8 (0.94)	6.7 (0.93)	6.8 (0.94)	6.6 (0.87)
CRP, mg/dl	2.5 (3.86)	2.6 (3.08)	2.5 (4.11)	2.5 (3.16)
ESR, mm/h	45.5 (25.35)	50.6 (29.10)	45.7 (23.28)	46.7 (28.72)

Data are mean (SD) unless stated otherwise.

^aTotal patients with at least one treatment.

CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score based on 28 joint count; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; NA, not available; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count.